InvestSMART

PYC Therapeutics Limited (ASX: PYC) - Announcements

Current share price for PYC : $2.825 0.085 (2.92%)+

ASX company news and announcements for PYC Therapeutics Limited (PYC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All PYC Therapeutics Limited (PYC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than PYC Therapeutics Limited (PYC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for PYC Therapeutics Limited (PYC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2,778 Notice of General Meeting/Proxy Form 12 Jun 2026 3:55PM $1.215 $2.825 risen by 132.51%
$2,778 Change to CEO remuneration 26 May 2026 7:23PM $1.380 $2.825 risen by 104.71%
$2,778 2026 Q2 Investor Webinar Presentation 22 May 2026 9:17AM $1.305 $2.825 risen by 116.48%
$2,778 Ceasing to be a substantial holder 18 May 2026 7:06PM $1.325 $2.825 risen by 113.21%
$2,778 Investor Webinar 12 May 2026 9:07AM $1.265 $2.825 risen by 123.32%
$2,778 Notification of cessation of securities - PYC 11 May 2026 6:56PM $1.265 $2.825 risen by 123.32%
$2,778 PKD - Initiation of Multiple Dose Clinical Trial 7 May 2026 9:03AM $1.165 $2.825 risen by 142.49%
$2,778 Presentation of Ophthalmology Clinical Trial Data at ARVO 4 May 2026 9:14AM $1.225 $2.825 risen by 130.61%
$2,778 Exercise of Options and Cleansing Notice 28 Apr 2026 6:44PM $1.305 $2.825 risen by 116.48%
$2,778 Application for quotation of securities - PYC 28 Apr 2026 6:34PM $1.305 $2.825 risen by 116.48%
$2,778 Quarterly Activities/Appendix 4C Cash Flow Report 28 Apr 2026 9:12AM $1.310 $2.825 risen by 115.65%
$2,778 Orphan Drug Designation Granted for RP11 by EMA 27 Apr 2026 9:48AM $1.295 $2.825 risen by 118.15%
$2,778 ADOA Program - SRC Approve Progression to Multi-Dose Study 15 Apr 2026 10:53AM $1.210 $2.825 risen by 133.47%
$2,778 Change in substantial holding 1 Apr 2026 8:25PM $1.165 $2.825 risen by 142.49%
$2,778 Change of Director's Interest Notice RH 27 Mar 2026 1:17PM $1.113 $2.825 risen by 153.93%
$2,778 PKD - Presentation at World Congress of Nephrology 27 Mar 2026 9:58AM $1.170 $2.825 risen by 141.45%
$2,778 ADOA Program - Presentation at NANOS 2026 24 Mar 2026 9:01AM $1.200 $2.825 risen by 135.42%
$2,778 Regulatory Alignment on Registrational Trial Requirements 16 Mar 2026 9:19AM $1.415 $2.825 risen by 99.65%
$2,778 Change of Director's Interest Notice RH IC 10 Mar 2026 6:41PM $1.470 $2.825 risen by 92.18%
$2,778 Application for quotation of securities - PYC 9 Mar 2026 7:55PM $1.480 $2.825 risen by 90.88%
$2,778 Application for quotation of securities - PYC 6 Mar 2026 9:46AM $1.485 $2.825 risen by 90.24%
$2,778 Joint Company Secretary Appointment 4 Mar 2026 7:11PM $1.470 $2.825 risen by 92.18%
$2,778 Completion of Retail Entitlement Offer 4 Mar 2026 9:29AM $1.485 $2.825 risen by 90.24%
$2,778 PKD Clinical Trial - Approval to Escalate Dosing 27 Feb 2026 8:04AM $1.495 $2.825 risen by 88.96%
$2,778 Change in substantial holding 25 Feb 2026 9:35AM $1.490 $2.825 risen by 89.60%

26 - 50 of 943 results

Page 2 of 38

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.